Nursing research progress of Trop-2 targeting antibody-drug conjugates in the treatment of advanced solid tumors
10.3781/j.issn.1000-7431.2024.2405-0311
- VernacularTitle:靶向Trop-2抗体药物偶联物治疗晚期实体瘤的护理研究进展
- Author:
Min WU
1
;
Mengting JI
1
Author Information
1. 上海交通大学医学院附属仁济医院护理部,上海 200127
- Publication Type:Journal Article
- Keywords:
Antibody-drug conjugate;
Trophoblast cell surface antigen 2;
Advanced solid tumors;
Clinical Trial;
Adverse events,Nursing interventions
- From:
Tumor
2024;44(7):786-792
- CountryChina
- Language:Chinese
-
Abstract:
Antibody-drug conjugate(ADC)is a novel targeted drug composed of monoclonal antibodies,cytotoxic drugs,and their chemical linkers.Among them,ADC drugs targeting trophoblast cell surface antigen 2(Trop-2)are currently one of the research hotspots.Since the first Trop-2 targeted ADC,sacituzumab govitecan(SG),was approved by the FDA in April 2021,multiple Trop-2 targeted ADCs such as Dato-DXd,SKB264,ESG-401 and SHR-A1921 are currently undergoing clinical trials.The Trop-2 targeted ADCs have achieved clinical efficacy,but the related adverse events were reported.Furthermore,both the monoclonal antibody and cytotoxic drug of ADC may lead to adverse events.Therefore,it is particularly important to improve drug-related adverse events through pertinent nursing assessments and interventions during clinical trials.The official websites of the National Institutes of Health,the Drug Evaluation Center of the National Medical Products Administration,the Food and Drug Administration,China National Knowledge Infrastructure,Wanfang Data,PubMed,Web of Science and other related databases were searched to review the application of ADC drugs targeting Trop-2 in advanced solid malignant tumors,summarizing the common adverse events and the corresponding nursing interventions of such drugs,and providing references for clinical trials.
